Related Experiment Videos
Prolonged administration of FTY720 does not cause renal toxicity in mice
V R Galvão1, M Ginoza, M Franco
1Sâo José do Rio Preto Medicine School, São Paulo, Brazil. valquiriabueno@hotmail.com
Transplantation Proceedings
|April 6, 2005
Summary
FTY720, a novel immunosuppressant, prevents allograft rejection by modulating lymphocyte migration. This study found FTY720 has no significant renal toxicity in mice, suggesting its potential as an add-on therapy for transplant recipients.
Area of Science:
- Immunology
- Pharmacology
- Nephrology
Background:
- Calcineurin-inhibitor immunosuppression is standard for preventing allograft rejection but causes renal toxicity.
- FTY720 modulates immune responses by altering lymphocyte trafficking, potentially offering an alternative or adjunct therapy.
- The long-term nephrotoxic effects of continuous FTY720 administration require further investigation.
Purpose of the Study:
- To evaluate the potential nephrotoxicity of FTY720 when administered continuously.
- To assess the safety and efficacy of FTY720 as an add-on therapy in transplantation.
Main Methods:
- Oral administration of FTY720 (1 mg/kg/day) to C57BL/6 mice for 21 days.
- Weekly monitoring of renal function and structure.
- Evaluation of body weight changes.
Main Results:
- FTY720 administration at 1 mg/kg/day resulted in impaired body weight gain.
- No significant adverse effects on renal function or structure were observed.
- FTY720 demonstrated no significant nephrotoxicity in this short-term study.
Conclusions:
- FTY720 may be a viable option for preventing allograft rejection without causing kidney damage.
- FTY720 could serve as a beneficial add-on therapy for transplant recipients already on calcineurin inhibitors.
- Further long-term studies are warranted to confirm the safety profile of FTY720.